Evidence check: Pharmakogenetik Medicheck in the context of blood sugar

The pharmacogenetics Medicheck offered by MyBody-X in the context of blood sugar requires cautious evaluation. While certain genetic variants (e.g., TCF7L2, KCNJ11, PPARG) are known to modestly influence response to antidiabetic drugs like sulfonylureas or metformin – evidence is human-moderate – effect sizes are small and clinical utility for individuals remains uncertain. Current guidelines (e.g., from the German Diabetes Association) do not recommend routine pharmacogenetic testing before therapy. Consumer kits often test only a limited set of variants, and interpretation without medical supervision can be misleading. The test does not measure blood sugar directly and cannot replace established diagnostics such as HbA1c or fasting glucose. Overall evidence is 'mixed': mechanistically plausible but insufficiently validated in practice. Any medication changes should be made only by a physician.